静脉血栓栓塞症各亚型血栓复发风险的分子决定因素
该研究基于8个队列6355例静脉血栓栓塞症(VTE)患者(含1775例复发)的基因组数据,分析VTE复发的分子决定因素,按性别和首发VTE临床表现进行亚组分析,共识别28个分子标志物,发现GPR149/MME位点及KNG1、FGG与复发相关,孟德尔随机化分析识别7种蛋白为复发风险因素。
要点
- 全基因组关联研究识别出1个与VTE复发相关的位点GPR149/MME。
- 在已知与首发VTE相关的变异中,KNG1和FGG与复发相关。
- 孟德尔随机化分析识别7种蛋白与VTE复发风险相关,包括凝血因子XI、凝血因子VIII、血管性血友病因子等。
核心结论
- 特定遗传位点和蛋白通路影响VTE复发,为潜在治疗靶点提供线索。
- 仍需进一步研究阐明这些关联背后的生物学机制。
研究设计与样本
- 分析8个队列6355例VTE患者(含1775例复发)的基因组结构,并按性别和首发VTE临床表现进行亚组分析。
主要发现
- 全基因组关联研究识别1个与VTE复发相关的位点GPR149/MME。
- 在已知与首发VTE相关的变异中,KNG1和FGG与复发相关。
- 孟德尔随机化分析识别7种蛋白为复发风险因素:凝血因子XI、凝血因子VIII、血管性血友病因子、组织血型ABO系统转移酶和Golgi膜蛋白2血浆水平升高;前蛋白转化酶枯草溶菌素/kexin 9型和前白细胞介素-16水平降低。
- 亚组分析发现18个与VTE复发相关的分子决定因素,亚组间差异显著;例如外显子变异SLC4A1 p.Glu40Lys在肺栓塞患者中显著相关,而在深静脉血栓患者中无效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is a frequent (annual incidence of 1-2 per 1000 individuals) and potentially life-threatening (case-fatality rate up to 10%) disease. VTE is associated with serious short-term and long-term complications, including a recurrence rate approaching 20% within 5 years. Anticoagulant therapy, the mainstay of VTE treatment, drastically reduces the risk of early VTE recurrence, but it exposes patients to a substantial risk of bleeding. We analyzed the genomic architecture of VTE recurrence using data from 6355 patients across 8 cohorts (including 1775 recurrences), enriched by subgroup analyses, according to sex and clinical manifestation of first VTE, which led to the identification of 28 molecular markers. Through genome-wide association studies, we identified 1 locus associated with VTE recurrence, GPR149/MME. Among all variants known to be associated with first VTE, KNG1, and FGG were associated with recurrence. Additionally, Mendelian randomization analyses identified 7 proteins as risk factors for recurrence: elevated plasma levels of coagulation factor XI, coagulation factor VIII, von Willebrand factor, histo-blood group ABO system transferase, and Golgi membrane protein 2; and decreased levels of proprotein convertase subtilisin/kexin 9 and pro-interleukin-16. Subgroup analyses revealed 18 molecular determinants associated with VTE recurrence, with notable differences between subgroups. For example, the exonic variant SLC4A1 p.Glu40Lys was significantly associated in patients who experienced pulmonary embolism but showed no effect in those with deep vein thrombosis. These findings emphasize the role of specific genetic loci and protein pathways in influencing VTE recurrence and provide valuable insights into potential therapeutic targets. Further research is needed to clarify the biological mechanisms driving these associations.
引用
- Munsch G, Thibord F, Bezerra OC, et al. Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes. Blood. 2025. PMID: 40811855. doi:10.1182/blood.2024027879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。